Background {#Sec1}
==========

Cancer is the second leading cause of morbidity and mortality worldwide \[[@CR1]\]. One major feature of cancer is uncontrolled cell proliferation, which can then invade adjacent parts of the body and spread to other organs, the latter process is referred as metastases, which are the major cause of death from cancer \[[@CR2]\]. The most common causes of cancer deaths are due to cancers of the: lung (1.59 million deaths), liver (745,000 deaths), stomach (723,000 deaths), colorectal (694,000 deaths), breast (521,000 deaths) and esophageal (400,000 deaths) \[[@CR1], [@CR2]\]. Alongside, metabolic alterations and tumor hypoxia have consistently been identified as classical features with aggressive malignancy \[[@CR3], [@CR4]\]. Hypoxia regulates tumor cell phenotype mainly by altering genes that are sensitive to oxygen pressure \[[@CR5]\]. However, the exact mechanism of carcinogenesis is yet to be elucidated. In recent years, an increasing number of studies have focused on understanding the relationship between genetic factors and cancer risk \[[@CR3], [@CR4]\]. Through the years, it has become well accepted that single nucleotide polymorphisms (SNPs) are the most common and effective type of genetic variations studied in association with disease susceptibility and are the markers of many complex diseases \[[@CR6]\].

Hypoxia inducible factor 1α (HIF1A), is a transcription factor that has major impacts in the process of development and progression of cancers \[[@CR7]\]. HIF1A regulates the expression of over 100 genes that control the major cellular functions including apoptosis, cell proliferation, glucose metabolism, erythropoiesis, iron metabolism and angiogenesis. It is a master regulator of oxygen homeostasis \[[@CR7]\]. In the scientific community, HIF1A has been a research focus and a number of SNPs within HIF1A gene have been identified in association with cancers, with the most widely studied polymorphisms are C1772T (rs11549465) and G1790A (rs11549467) polymorphisms \[[@CR8]--[@CR38]\]. These two SNPs are located within the same domain (ODD/ pVHL) in exon 12 of the HIF1A gene \[[@CR8], [@CR9]\]. Recently a meta-analysis has revealed that C1772T is not in substantial linkage disequilibrium (LD) with G1790A \[[@CR38]\]. A number of studies have suggested that these two nonsynonymous mutations might alter the transcriptional activity of HIF1A gene by causing structural changes with varied stability, which in turn, might influence the downstream target genes expression and regulation \[[@CR8], [@CR9], [@CR38]\]. In the recent years, a good number of studies have investigated the impact of HIF1A polymorphisms on cancer risk in different populations; however reported results varied across studies and remain inconclusive \[[@CR10]--[@CR38]\]. In this study, the effect of rs11549465 (1772 C/T) and rs11549467 (1790 G/A) polymorphisms of HIF1A gene and its association with cancers were investigated systematically through meta-analysis.

Methods {#Sec2}
=======

Search study and study selection {#Sec3}
--------------------------------

The PubMed, PubMed Central and Google Scholar databases were searched systematically to retrieve compatible and pertinent peer reviewed publications of empirical studies. Published articles of last 15 years (ended on December 2014), in English language were only considered for this study. The search terms included were (1) HIF1A, (2) GWAS, (3) SNPs, (4) polymorphisms, (5) C1772T/ P582S, (6) A1790G/ A588T, (7) case-control study, and (8) cancer.

Eligibility criteria {#Sec4}
--------------------

Two authors independently investigated titles and abstracts of all the articles. Irrelevant and incompatible studies were excluded primarily. For final review, criteria's for further study elimination were: if (1) the study population was not defined completely; (2) it is not a case-control study; (3) not a genome wide association study; (4) incomplete information of allele frequency; and (5) the year of study conducted was not specified. Also, reviews, editorials, meta-analysis and non-human researches were excluded. Only case-control studies, genome wide association study (GWAS) and human researches were considered for the final review. Further, the references of the selected studies were screened carefully for incorporation of additional relevant studies. Only English language articles were considered for this study. Discrepancies and difficulties were discussed with corresponding authors where necessary. Following information were extracted from each study: (1) authors name, (2) year of study, (3) ethnicity of the study subjects, (4) cancer type and (5) allelic frequency (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of study selection for HIF1A 1772 C/T and 1790 G/A polymorphisms; where "n" in the boxes is the number of corresponding studies

Meta-analysis {#Sec5}
-------------

For HIF1A 1772 C/T polymorphism 22 case-control studies were included of sample size 19024 and for 1790 G/A polymorphism 19 case-control studies were included with sample size 10654. The meta-analysis was prepared in accordance with PRISMA statement \[[@CR39]\].

Statistical analysis {#Sec6}
--------------------

Meta-analysis of genome wide association studies (GWAS) of HIF1A were conducted for two polymorphisms, 1772 C/T and 1790 G/A using odds ratios (ORs). A slightly amended estimator of OR was used to avoid the computation of reciprocal of zeros among observed values in the calculation of the original OR \[[@CR40]\]. Pooled ORs with 95 % CIs were calculated using random effects model (REM) incorporating the inverse variance weighted method \[[@CR41]\]. Heterogeneity among studies was assessed using the Q statistic \[[@CR42]\] and quantified using I\^2 index \[[@CR43]\]. Subgroup analyses were carried out by cancer type and ethnicity. The Hardy Weinberg Equilibrium (HWE) test was performed for the controls of each study. The studies with control not in HWE were supervised for sensitivity analysis. Publication bias was assessed visually by conventionally constructed funnel plot where the inverse of the standard error (1/se) of the effect estimates were plotted against the logarithm transformation of Odds Ratios \[log(OR)\] \[[@CR44]\]. Furthermore, Egger's test was performed to provide quantitative evidence of publication bias \[[@CR45]\]. "Gap: Genetic analysis package" was used to perform the Hardy Weinberg Equilibrium (HWE) test \[[@CR46], [@CR47]\]. All analyses were conducted using "meta" package in R environment \[[@CR46]\].

Summary measures {#Sec7}
----------------

Odds Ratios (OR) with a 95 % confidence interval (CI) were calculated to evaluate the genotype contrasts. The genotype contrasts for the HIF1A 1772 C/T polymorphisms were: homozygote comparison \[TT versus CC\], heterozygote comparison \[CT versus CC\], and dominant model \[TT + CT versus CC\], recessive model \[TT versus CT + CC\] and T allele versus C allele. For HIF1A 1772 C/T polymorphism, three studies were found with genotype information of CC and CT + TT. These three studies were included only to evaluate genotype contrast of dominant model \[TT + CT vs. CC\]. The genotype contrasts for the HIF1A 1790 G/A polymorphism were: homozygote comparison \[AA versus GG\], heterozygote comparison \[GA versus GG\] and dominant model \[AA + GA versus GG\], recessive model \[AA versus GA + GG\] and \[G versus A allele\].

Results and discussion {#Sec8}
======================

Study characteristics {#Sec9}
---------------------

In the meta-analysis of the HIF1A 1772 C/T polymorphism, ten different types of cancers consisted of 22 studies with 8149 cancer cases and 10,875 controls were included. The types of cancer included in these studies were prostate cancer, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, oral squamous cell carcinoma (OSCC), head-neck cancer, cervical cancer, bladder carcinoma and pancreatic cancer. For the following cancer types: head-neck, cervical, bladder and pancreatic only one study of each were found for the final review. So, these cancer types with single studies were incorporated in subgroup analysis as Other Cancers (Table [1](#Tab1){ref-type="table"}).Table 1Characteristic of eligible studies included in meta-analysis of HIF1A 1772 C/T polymorphismStudyYearCountryEthnicityCancerCase/ControlHWEClifford et al. \[[@CR8]\]2001UKCaucasianRenal cell carcinoma35/1430.018 (N)Tanimoto et al. \[[@CR9]\]2003JapaneseAsianHead-neck cancer55/1100.545 (Y)Ollerenshawa et al. \[[@CR10]\]2004EuropeanCaucasianRenal cell carcinoma160/162\<0.001 (N)Chau et al. \[[@CR11]\]2005USAMixedProstate cancer196/196\<0.001 (N)Franse et al. \[[@CR12]\]2006SwedishCaucasianColorectal cancer198/2580.916 (Y)Konac et al. \[[@CR13]\]2007TurkishCaucasianCervical cancer32/1070.229 (Y)Li et al. \[[@CR14]\]2007AmericanMixedProstate cancer1041/12340.159 (Y)Lee et al. \[[@CR15]\]2008KoreanAsianBreast cancer1332/13690.250 (Y)Kim et al. \[[@CR16]\]2008KoreanAsianBreast cancer90/1020.641 (Y)Nadaoka et al.^a^ \[[@CR17]\]2008JapaneseAsianTransitional cell carcinoma of bladder219/461Jacobs et al. \[[@CR18]\]2008AmericanMixedProstate cancer1420/14500.041 (N)Foley et al. \[[@CR19]\]2009IrelandCaucasianProstate cancer95/1880.623 (Y)Morris et al. \[[@CR20]\]2009PolishCaucasianRenal cell carcinoma332/3130.083 (Y)Chen et al. \[[@CR21]\]2009TaiwaneseAsianOral squamous cell carcinoma (OSCC)174/3470.722 (Y)Shieh et al. \[[@CR22]\]2010TaiwanAsianOral squamous cell carcinoma (OSCC)305/960.710 (Y)Knechtel et al.^a^ \[[@CR23]\]2010AustriaCaucasianColorectal cancer368/2156Kang et al.^a^ \[[@CR24]\]2011KoreanAsianColorectal cancer50/50Putra et al. \[[@CR25]\]2011JapaneseAsianLung cancer83/1100.545 (Y)Wang et al. \[[@CR26]\]2011ChineseAsianPancreatic cancer263/2710.352 (Y)Kuo et al. \[[@CR27]\]2012TaiwaneseAsianLung cancer285/3000.132 (Y)Li et al. \[[@CR28]\]2012ChinaAsianProstate cancer662/7160.267 (Y)Fraga et al. \[[@CR29]\]2014PortugueseCaucasianProstate cancer754/7360.400 (Y)^a^Frequency of genotypes "CT + TT". *HWE* Hardy-Weinberg Equilibrium

For the meta-analysis of HIF1A 1790 G/A polymorphism, 19 studies with eleven different cancer types consisted of 4681 cancer cases and 5973 controls were included. The cancer types associated with this polymorphism were: renal cancer, prostate cancer, breast cancer, lung cancer, oral squamous cell carcinoma (OSCC), head-neck cancer, gastric cancer, hepatocellular carcinoma, lymph node metastasis, pancreatic cancer and colorectal cancer. For final review, only one study of each of the following cancer types was found: head-neck cancer, gastric cancer, hepatocellular carcinoma, lymph node metastasis, pancreatic cancer and colorectal cancer. These cancer types with single studies were incorporated in subgroup analysis as Other Cancers (Table [2](#Tab2){ref-type="table"}).Table 2Characteristic of eligible studies included in meta-analysis of HIF1A 1790G/A polymorphismStudyYearCountryEthnicityCancerCase/ControlHWEClifford et al. \[[@CR8]\]2001CaucasianCaucasianRenal cancer48/1440.866(Y)Tanimoto et al. \[[@CR9]\]2003JapanAsianHead neck squeamish cell carcinoma55/1100.655(Y)Ollerenshaw et al. \[[@CR10]\]2004CaucasianCaucasianRenal cancer146/288\<0.001(N)Fransen et al. \[[@CR12]\]2006SwedenCaucasianColorectal cancer198/2560.775(Y)Orr-Urtreger et al. \[[@CR30]\]2007IsraelCaucasianProstate cancer200/3000.954(Y)Li et al. \[[@CR14]\]2007USAMixedProstate cancer1066/12640.810(Y)Apaydin et al. \[[@CR31]\]2008TurkeyCaucasianBreast cancer102/1020.840(Y)Kim et al. \[[@CR16]\]2008KoreaAsianBreast cancer90/1020.06(Y)Muñoz et al. \[[@CR32]\]2009SpainCaucasianOral squamous cell carcinoma64/1390.693(Y)Chen et al. \[[@CR21]\]2009TaiwaneseAsianOral squamous cell carcinoma174/3470.701(Y)Morris et al. \[[@CR20]\]2009polishCaucasianRenal cancer325/3090.662(Y)Li K et al. \[[@CR33]\]2009TibetanAsianGastric cancer87/1060.764(Y)Hsiao et al. \[[@CR34]\]2010TaiwanAsianHepatocellular carcinoma102/3470.701(Y)Putra et al. \[[@CR25]\]2011JapanAsianLung cancer83/1100.655(Y)Wang et al. \[[@CR26]\]2011JapanAsianPancreatic cancer263/2710.486(Y)Kuo et al. \[[@CR27]\]2012ChinaAsianLung cancer285/3000.154(Y)Li et al. \[[@CR28]\]2012ChinaAsianProstate cancer662/7160.554(Y)Mera-Mene et al. \[[@CR35]\]2012SpainCaucasianLymph node metastasis111/1390.693(Y)Qin et al. \[[@CR36]\]2012AsianAsianRenal cancer620/6230.411(Y)*HWE* Hardy-Weinberg Equilibrium

Association of the HIF1A 1772 C/T polymorphism with cancer risk {#Sec10}
---------------------------------------------------------------

The pooled ORs for overall cancer suggested that the HIF1A 1772 C/T polymorphism was significantly associated with increasing cancer risk for the dominant model \[TT + CT vs. CC: OR 1.30, 95 % CI (1.06-1.59), *p*-value: 0.0115\] and \[T vs. C allele: OR 1.32, 95 % CI (1.07-1.63), *p*-value: 0.0098\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plot of HIF1A polymorphism 1772 C/T for overall cancer

### Subgroup analyses performed by cancer type {#Sec11}

The subgroup analyses of prostate cancer, colorectal cancer, breast cancer and oral squamous-cell carcinoma suggested no significant association of the HIF1A 1772 C/T polymorphism. However, the subgroup analyses of renal cell carcinoma suggested that the HIF1A 1772 C/T polymorphism is significantly associated with lowering renal cell carcinoma risk in homozygote comparison \[TT vs. CC: OR 0.27, 95 % CI (0.08-0.90), *p*-value:0.0335\]. Interestingly, the results of subgroup analyses of lung cancer suggested that the HIF1A 1772 C/T polymorphism is highly associated with increasing lung cancer risk in homozygote comparison \[TT vs. CC: OR 4.88, 95 % CI (2.42-9.84), *p*-value: \<0.0001\], recessive model \[TT vs. CT + CC: OR 4.04, 95 % CI (2.02-8.08), *p*-value:\<0.0001\]. The subgroup analyses of Other Cancers suggested that the HIF1A 1772 C/T polymorphism is highly associated with increasing Other Cancer risk in homozygote comparison \[TT vs. CC: OR 27.20, 95 % CI (5.04-146.78), *p*-value: 0.0001\], heterozygote comparison \[CT vs. CC: OR 2.16, 95 % CI (1.46-3.18), *p*-value: 0.0056\], dominant model \[TT + CT vs. CC: OR 1.92, 95 % CI (1.17-3.14), *p*-value: 0.0093\], recessive model \[TT vs. CT + CC: OR 17.5, 95 % CI (3.49-87.70), *p*-value: 0.0005\] and \[T vs. C allele: OR 2.42, 95 % CI (1.55-3.77), *p*-value: \<0.0001\] (Table [3](#Tab3){ref-type="table"}).Table 3Meta-analysis of the HIF1A 1772 C/T polymorphism association with cancerTT vs. CCCT vs. CCTT + CT vs. CCTT vs. CT + CCT vs. CStudy numberSample sizeOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOverall cancer22190241.52 \[0.73--3.18\]0.26481.23 \[1.00--1.53\]0.05361.30 \[1.06--1.59\]0.01151.64 \[0.94--2.85\]0.08321.32 \[1.07--1.63\]0.0098Prostate cancer686880.84 \[0.47--1.49\]0.54491.34 \[0.95--1.87\]0.09131.33 \[0.95--1.87\]0.09820.81 \[0.47--1.40\]0.45351.29 \[0.94--1.76\]0.1178Colorectal cancer330801.91 \[0.32--11.58\]0.48010.83 \[0.50--1.39\]0.48171.24 \[0.77--2.01\]0.37561.97 \[0.33--11.90\]0.46030.94 \[0.59--1.49\]0.7833Renal cancer311450.27 \[0.08--0.90\]0.03350.40 \[0.12--1.34\]0.13690.43 \[0.15--1.20\]0.10821.08 \[0.44--2.64\]0.87030.84 \[0.58--1.22\]0.3548Breast cancer228935.18 \[0.88--30.38\]0.06831.00 \[0.77--1.29\]0.99641.05 \[0.81--1.35\]0.72215.18 \[0.88--30.36\]0.06841.09 \[0.86--1.39\]0.4701Lung cancer27784.88 \[2.42--9.84\]\< 0.00011.56 \[0.94--2.61\]0.0881.67 \[0.79--3.54\]0.18324.04 \[2.02--8.08\]\< 0.00011.68 \[0.77--3.64\]0.1908OSCC29226.14 \[0.25--151.49\]0.26731.29 \[0.70--2.37\]0.41421.36 \[0.75--2.49\]0.31276.01 \[0.24--148.26\]0.27291.43 \[0.79--2.56\]0.2348Other cancers4151827.20 \[5.04--146.78\]0.00012.16 \[1.46--3.18\]0.00561.92 \[1.17--3.14\]0.009317.5 \[3.49 -- 87.70\]0.00052.42 \[1.55--3.77\]\< 0.0001Ethnicity Caucasian860370.97 \[0.24--3.93\]0.96541.09 \[0.60--2.00\]0.77511.19 \[0.75--1.89\]0.45281.48 \[0.65--3.39\]0.3521.31 \[0.84--2.06\]0.237 Asian1174504.98 \[2.66--9.31\]\< 0.00011.30 \[1.01--1.690.04551.41 \[1.08--1.84\]0.01094.28 \[2.31--7.95\]\< 0.00011.43 \[1.07--1.90\]0.0156 Mixed355370.82 \[0.36--1.87\]0.64081.16 \[1.00--1.65\]0.41781.16 \[0.79--1.70\]0.45260.79 \[0.37--1.71\]0.55441.14 \[0.78--1.67\]0.505

### Subgroup analyses by ethnicity group {#Sec12}

The analyses data for the HIF1A 1772 C/T polymorphism suggested that there was no significant effect on the Caucasian population. However, the subgroup analyses of the Asian population suggested that the HIF1A 1772 C/T polymorphism was significantly associated with increasing cancer risk in homozygote comparison \[TT vs. CC: OR 4.98, 95 % CI (2.66-9.31), *p*-value: \<0.0001\], heterozygote comparison \[CT vs. CC: OR 1.30, 95 % CI (1.01-1.69), *p*-value: 0.0455\], dominant model \[TT + CT vs. CC: OR 1.41, 95 % CI (1.08-1.84), *p*-value: 0.0109\], recessive model \[TT vs. CT + CC: OR 4.28, 95 % CI (2.31-7.95), *p*-value:\<0.0001\] and \[T vs. C allele: OR 1.43, 95 % CI (1.07-1.90), *p*-value: 0.0156\] (Table [3](#Tab3){ref-type="table"}). The subgroup analyses of mixed ethnic groups suggested that there were no significant association between HIF1A 1772 C/T polymorphism and cancer risk (Table [3](#Tab3){ref-type="table"}).

Sources of heterogeneity {#Sec13}
------------------------

There were significant heterogeneity observed in the analyses of HIF1A 1772 C/T polymorphism for overall cancer heterozygote comparison \[CT vs. CC: Q = 69.67, d.f = 18, *p*-value 0.0001, I\^2 = 74.2 % (59.5 %-83.5 %)\], dominant model \[TT + CT vs. CC: Q = 90.25, d.f = 21, *p* \<0.0001, I\^2 = 76.7 % (65.1 %-84.5 %)\], and \[T vs. C allele: Q = 96.87, d.f = 18, *p* \<0.0001, I\^2 = 81.4 % (71.9 %-87.7 %). To detect the sources of heterogeneity subgroup analyses by cancer type and ethnicity group were performed. In the subgroup analyses by cancer type heterogeneity was significantly reduced. The results suggested that the studies in prostate cancer, renal cell carcinoma, lung cancer, Caucasian ethnicity and Asian ethnicity were the main sources of heterogeneity (Additional file [1](#MOESM1){ref-type="media"}).

Association of the HIF1A 1790 G/A polymorphism with cancer risk {#Sec14}
---------------------------------------------------------------

The pooled ORs for overall cancer suggested that the HIF1A 1790 G/A polymorphism was significantly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 5.10, 95 % CI (3.12-8.33), *p*-value: \<0.0001, heterozygote comparison \[GA vs. GG: OR 1.74, 95 % CI (1.20-2.52), *p*-value: 0.0033, dominant model \[AA + GA vs. GG: OR 1.82, 95 % CI (1.26-2.62), *p*-value: 0.0014\], recessive model \[AA vs. GA + GG: OR 3.79, 95 % CI (2.34-6.15), *p*-value: \<0.0001\] and \[A vs. G allele: OR 1.82, 95 % CI (1.31-2.52), *p*-value: 0.0003\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot of the HIF1A polymorphism 1790 G/A for overall cancer

### Subgroup analyses by cancer type {#Sec15}

The analyzed data of prostate cancer suggested no significant association with the HIF1A 1790 G/A polymorphism. The subgroup analyses of renal cancer suggested that the HIF1A 1790 G/A polymorphism was significantly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 5.11, 95 % CI (2.24-11.66), *p*-value: 0.0001\], recessive model \[AA vs. GA + GG: OR 3.05, 95 % CI (1.36-6.84), *p*-value: 0.0068\] whereas the subgroup analyses of breast cancer showed that the HIF1A 1790 G/A polymorphism was significantly associated with decreasing cancer risk for \[A vs. G allele: OR 0.30, 95 % CI (0.09-1.00), *p*-value: 0.0495\]. The subgroup analyses of lung cancer suggested that the HIF1A 1790 G/A polymorphism was significantly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 5.41, 95 % CI (2.74-10.69), *p*-value: \<0.0001\], heterozygote comparison \[GA vs. GG: OR 1.76, 95 % CI (1.25-2.49), *p*-value: 0.0013\], dominant model \[AA + GA vs. GG: OR 2.20, 95 % CI (1.60-3.03), *p*-value:\<0.0001\], recessive model \[AA vs. GA + GG: OR 4.51, 95 % CI (2.31-8.81), *p*-value:\<0.0001\] and \[A vs. G allele: OR 2.31, 95 % CI (1.77-3.02), *p*-value: \<0.0001\]. Also, the subgroup analyses of oral squamous cell carcinoma (OSCC) suggested that the HIF1A 1790 G/A polymorphism was significantly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 12.68, 95 % CI (1.43-112.64), *p*-value: 0.0227\], heterozygote comparison \[GA vs. GG: OR 4.69, 95 % CI (1.96-11.21), *p*-value: 0.0005\], dominant model \[AA + GA vs. GG: OR 5.17, 95 % CI (1.99-13.43), *p*-value: 0.0008\], recessive model \[AA vs. GA + GG: OR 10.12, 95 % CI (1.14-89.72), *p*-value: 0.0376\] and \[A vs. G allele: OR 5.00, 95 % CI (2.10-11.97), *p*-value: 0.0003\] (Table [4](#Tab4){ref-type="table"}). The subgroup analyses of Other Cancers suggested that the HIF1A 1790 G/A polymorphism is highly associated with increasing Other Cancer risk heterozygote comparison \[GA vs. GG: OR 1.96, 95 % CI (1.05-3.65), *p*-value: 0.0336\], dominant model \[AA + GA vs. GG: OR 1.96, 95 % CI (1.05-3.67), *p*-value: 0.0341\], and \[A vs. G allele: OR 1.91, 95 % CI (1.06-3.44), *p*-value: 0.0306\] (Table [4](#Tab4){ref-type="table"}).Table 4Meta-analysis of the HIF1A 1790 G/A polymorphism association with cancerAA vs. GGGA vs. GGAA vs. GA + GGAA + GA vs. GGA vs. GStudy numberSample sizeOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOR (95 % CI)*p* valueOverall19106545.10 \[3.12--8.33\]\< 0.00011.74 \[1.20--2.52\]0.00333.79 \[2.34--6.15\]\< 0.00011.82 \[1.26--2.62\]0.00141.82 \[1.31--2.52\]0.0003Renal cancer425035.11 \[2.24--11.66\]0.00011.51 \[0.45--5.05\]0.50383.05 \[1.36--6.84\]0.00681.58 \[0.49--5.03\]0.4421.53 \[0.60--3.92\]0.3747Prostate cancer342083.35 \[0.14--82.30\]0.45971.41 \[0.96--2.08\]0.08223.25 \[0.13--79.90\]0.47071.41 \[0.93--2.15\]0.10431.42 \[0.93--2.17\]0.1093Breast cancer23960.36 \[0.01--8.95\]0.53320.35 \[0.10--1.24\]0.10450.37 \[0.02--9.29\]0.54840.32 \[0.09--1.10\]0.07020.30 \[0.09--1.00\]0.0495Lung cancer27785.41 \[2.74--10.69\]\< 0.00011.76 \[1.25--2.49\]0.00134.51 \[2.31--8.81\]\< 0.00012.20 \[1.60--3.03\]\< 0.00012.31 \[1.77--3.02\]\< 0.0001OSCC272412.68 \[1.43--112.64\]0.02274.69 \[1.96--11.21\]0.000510.12 \[1.14--89.72\]0.03765.17 \[1.99--13.43\]0.00085.00 \[2.10--11.97\]0.0003Other cancers620453.77 \[0.15--93.07\]0.41711.96 \[1.05--3.65\]0.03363.10 \[0.13--76.51\]0.48871.96 \[1.05--3.67\]0.03411.91 \[1.06--3.44\]0.0306Ethnicity Caucasian826665.68 \[2.57--12.58\]\< 0.00011.43 \[0.54--3.74\]0.46913.42 \[1.57--7.45\]0.0021.50 \[0.58--3.85\]0.39871.52 \[0.68--3.42\]0.3103 Asian1049144.76 \[2.55--8.91\]\< 0.00011.94 \[1.38--2.72\]0.00014.05 \[2.1 --7.51\]\< 0.00012.04 \[1.44--2.87\]\< 0.00012.03 \[1.46--2.81\]\< 0.0001

### Subgroup analyses by ethnicity group {#Sec16}

For Caucasian population, the analyzed data suggested that the HIF1A 1790 G/A polymorphism was highly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 5.68, 95 % CI (2.57-12.58), *p*-value: \<0.0001\], recessive model \[AA vs. GA + GG: OR 3.42, 95 % CI (1.57-7.45), *p*-value: 0.002\]. For the Asian population, the subgroup analyses of ethnicity group suggested that the HIF1A 1790 G/A polymorphism was highly associated with increasing cancer risk for homozygote comparison \[AA vs. GG: OR 4.76, 95 % CI (2.55-8.91), *p*-value: \<0.0001\], heterozygote comparison \[GA vs. GG: OR 1.94, 95 % CI (1.38-2.72), *p*-value: 0.0001\], dominant model \[AA + GA vs. GG: OR 2.04, 95 % CI (1.44-2.87), *p*-value: \<0.0001\], recessive model \[AA vs. GA + GG: OR 4.05, 95 % CI (2.18-7.51), *p*-value: \<0.0001\] and \[A vs. G allele: OR 2.03, 95 % CI (1.46-2.81), *p*-value: \<0.0001\] (Table [4](#Tab4){ref-type="table"}).

Sources of heterogeneity {#Sec17}
------------------------

There were significant heterogeneity observed in the analyses of HIF1A 1790G/A polymorphism for overall cancer heterozygote comparison \[GA vs. GG: Q = 77.05, d.f = 18, *p*-value: \<0.0001, I\^2 = 76.6 % (63.8 %-84.9 %), dominant model \[AA + GA vs. GG: Q = 79.66, d.f = 18, *p*-value: \<0.0001, I\^2 = 77.4 % (65.1 %-85.4 %)\], and \[A vs. G allele: Q = 71.09, d.f = 18, *p*-value: \<0.0001, I\^2 = 74.7 % (60.4 %-83.8 %)\]. To detect the sources of heterogeneity subgroup analyses by cancer type and ethnicity group were performed. The results suggested that the studies in renal cell carcinoma, oral squamous cell carcinoma (OSCC), Caucasian ethnicity and Asian ethnicity were the main sources of heterogeneity (Additional file [2](#MOESM2){ref-type="media"}).

Publication bias {#Sec18}
----------------

To investigate the evidence of publication bias of the HIF1A 1772 C/T polymorphism for T versus C allele and HIF1A 1790 G/A polymorphism for G versus A allele funnel plot were used. The conventionally constructed funnel plot (log odds ratio \[log(OR\] vs 1/standard error, 1/se) of HIF1A polymorphism 1772 C/T for T vs. C allele suggested that there was evidence of publication bias (Fig. [4](#Fig4){ref-type="fig"}). Also the funnel plot of HIF1A polymorphism 1790 G/A for A vs. G allele suggested that there was evidence of publication bias (Fig. [4](#Fig4){ref-type="fig"}). However, the Egger's linear regression analyses suggested no evidence of significant publication bias in \[T vs C allele: t = 1.83, d.f = 17, *p*-value 0.0847\] for HIF1A 1772 C/T polymorphism. Also, for HIF1A 1790 G/A polymorphism results showed no significant evidence of publication bias in \[A vs G allele: t = -1.87, d.f = 17, *p*-value 0.0787\] (Additional file [3](#MOESM3){ref-type="media"}).Fig. 4Funnel plot of HIF1A polymorphism (**a**) 1772 C/T for T allele vs. C allele and (**b**) 1790 G/A for A allele vs. G allele; showing visual evidence of publication bias

Sensitivity analysis {#Sec19}
--------------------

Studies which were not in HWE were excluded to evaluate the stability of the acquired results. The statistical significance of the results was not shifted after omitting the studies which were not in HWE which confirmed the obtained results of the meta-analysis were stable and robust.

Conclusion {#Sec20}
==========

Results generated from this meta-analysis indicated that both 1772 C/T and 1790 G/A polymorphisms are significantly associated with increasing overall cancer risk. The subgroup analyses by cancer type showed that both 1772 C/T and 1790 G/A polymorphisms have significant association with lung cancer, whereas these two polymorphisms showed no significant association with prostate cancer. In oral squamous cell carcinoma (OSCC) subgroup analyses data showed that only 1790 G/A polymorphism has significant association whereas the HIF1A 1772 C/T polymorphism showed no significant association. However, the 1772 C/T polymorphism has indicated significantly decreased risk in renal cell carcinoma. Also, 1790 G/A polymorphism has increased the cancer risk significantly in both Caucasian and Asian ethnicity. Taken together all analyzed data, HIF1A could be a prognostic marker useful for early detection and diagnosis for cancers. In future, further experimental validations would be necessary to confirm the results.

Additional files {#Sec21}
================

Additional file 1:**Heterogeneity analysis of HIF1A 1772 C/T.** (XLSX 14 kb)Additional file 2:**Heterogeneity analysis of A polymorphism/A.** (XLSX 12 kb)Additional file 3:**Egger\'s linear regression analyses of HIF1A 1772 C/T and HIF1A 1790 G/A.** (DOCX 17 kb)

GWAS

:   Genome wide association studies

SNP

:   Single nucleotide polymorphism

REM

:   Random effects model

CI

:   Confidence interval

SE

:   Standard error

Log

:   Logarithm

HWE

:   Hardy-Weinberg Equilibrium

HIF1

:   Hypoxia- inducible factor -1

HIF1A

:   Hypoxia- inducible factor -1α

OR

:   Odds ratio

OSCC

:   Oral squamous cell carcinoma.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

Jesmin and MBH designed the research, MBH designed the experimental data analysis model and validate interpretation, MTA and AI collected, screened and analyzed the data. Jesmin, MBH and MTA analyzed and interpreted the result, drafted and revised the manuscript. All authors have read and approved the final manuscript.

This work was supported in part by NST Grant 39.012.002.01,03.021.2014-09/260 from the Ministry of Science & Technology (MOST), Government of the People's Republic of Bangladesh (to AI and Jesmin).
